Lonza launches liver cells for biopharma research

By Staff reporter

- Last updated on GMT

iStock/Dr_Microbe
iStock/Dr_Microbe
Lonza has launched a new range of cryopreserved liver cells for biopharmaceutical companies that want to assess the toxicity of their drugs.

The cell lines – which consist of human and animal hepatocytes– are designed for use in a variety of in-vitro​ applications, including studies into drug metabolism and toxicity, drug-transporter activity and drug-drug interactions.

A Lonza spokeswoman told us “These high-quality hepatocytes will support scientists with in-vitro​ drug metabolism and pharmacokinetic studies, as well as vital research into diseases such as Malaria and Hepatitis B.”

In addition, the Swiss life sciences supplier has developed supporting ADME-Tox products such as specialized hepatocyte media and cell culture systems.

The launch comes a year after Lonza bought​ US liver cell specialist Triangle Research Laboratories, whose role in the launch was acknowledged by Maureen Bunger, product manager for ADME-Tox Solutions.

By blending the extensive expertise of Lonza and TRL, our new hepatocyte portfolio will address the needs of the scientific community, offering hepatocytes that produce consistent and reliable results for ADME-Tox testing and for research into liver-associated diseases​.”

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers